Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

2.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

3.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK.

Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12.

4.

The double-edged sword of IFN-γ-dependent immune-based therapies.

John LB, Darcy PK.

Immunol Cell Biol. 2016 Jul;94(6):527-8. doi: 10.1038/icb.2016.37. Epub 2016 May 10. No abstract available.

PMID:
27167903
5.

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.

Yong CS, John LB, Devaud C, Prince MH, Johnstone RW, Trapani JA, Darcy PK, Kershaw MH.

Oncotarget. 2016 Jun 7;7(23):34582-98. doi: 10.18632/oncotarget.9149.

6.

Successful Outcome of Twin Gestation with Partial Mole and Co-Existing Live Fetus: A Case Report.

Rathod S, Rani R, John LB, Samal SK.

J Clin Diagn Res. 2015 Aug;9(8):QD01-2. doi: 10.7860/JCDR/2015/13038.6268. Epub 2015 Aug 1.

7.

Cross-talk between tumors can affect responses to therapy.

Devaud C, John LB, Westwood JA, Yong CS, Beavis PA, Schwendener RA, Darcy PK, Kershaw MH.

Oncoimmunology. 2015 Jun 17;4(7):e975572. eCollection 2015 Jul.

8.

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Devaud C, Westwood JA, Teng MW, John LB, Yong CS, Duong CP, Smyth MJ, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Dec 21;3(11):e963395. eCollection 2014 Nov.

9.

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.

Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK.

Cancer Immunol Res. 2015 May;3(5):506-17. doi: 10.1158/2326-6066.CIR-14-0211. Epub 2015 Feb 11.

10.

Foxp3 expression in macrophages associated with RENCA tumors in mice.

Devaud C, Yong CS, John LB, Westwood JA, Duong CP, House CM, Denoyer D, Li J, Darcy PK, Kershaw MH.

PLoS One. 2014 Sep 29;9(9):e108670. doi: 10.1371/journal.pone.0108670. eCollection 2014.

11.

Outcome of forceps delivery in a teaching hospital: A 2 year experience.

John LB, Nischintha S, Ghose S.

J Nat Sci Biol Med. 2014 Jan;5(1):155-7. doi: 10.4103/0976-9668.127316.

12.

Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor.

John LB, Chee TM, Gilham DE, Darcy PK.

Methods Mol Biol. 2014;1139:177-87. doi: 10.1007/978-1-4939-0345-0_16.

PMID:
24619680
13.

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy.

John LB, Kershaw MH, Darcy PK.

Oncoimmunology. 2013 Oct 1;2(10):e26286. Epub 2013 Oct 10.

14.

Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment.

Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK.

Oncoimmunology. 2013 Sep 1;2(9):e25962. Epub 2013 Aug 2. Review.

15.

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.

Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH.

Oncoimmunology. 2013 Aug 1;2(8):e25961. Epub 2013 Aug 22. Review.

16.

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH.

Mol Ther. 2014 Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19.

17.

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ, Darcy PK.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6. doi: 10.1073/pnas.1308209110. Epub 2013 Aug 20.

18.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.

Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.

19.

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.

Henderson MA, Yong CS, Duong CP, Davenport AJ, John LB, Devaud C, Neeson P, Westwood JA, Darcy PK, Kershaw MH.

Immunotherapy. 2013 Jun;5(6):577-90. doi: 10.2217/imt.13.37.

PMID:
23725282
20.

Engineering T cell function using chimeric antigen receptors identified using a DNA library approach.

Duong CP, Westwood JA, Yong CS, Murphy A, Devaud C, John LB, Darcy PK, Kershaw MH.

PLoS One. 2013 May 7;8(5):e63037. doi: 10.1371/journal.pone.0063037. Print 2013.

21.

Pegasus, the 'atypical' Ikaros family member, influences left-right asymmetry and regulates pitx2 expression.

John LB, Trengove MC, Fraser FW, Yoong SH, Ward AC.

Dev Biol. 2013 May 1;377(1):46-54. doi: 10.1016/j.ydbio.2013.02.017. Epub 2013 Mar 13.

22.

Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.

Quetglas JI, John LB, Kershaw MH, Alvarez-Vallina L, Melero I, Darcy PK, Smerdou C.

Oncoimmunology. 2012 Nov 1;1(8):1344-1354.

23.

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2012 Apr 1;72(7):1651-60. doi: 10.1158/0008-5472.CAN-11-2788. Epub 2012 Feb 7.

24.

The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity.

John LB, Ward AC.

Mol Immunol. 2011 May;48(9-10):1272-8. doi: 10.1016/j.molimm.2011.03.006. Epub 2011 Apr 7. Review.

PMID:
21477865
25.

Origins of adaptive immunity.

Liongue C, John LB, Ward A.

Crit Rev Immunol. 2011;31(1):61-71. Review.

PMID:
21395512
26.

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.

Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH.

Cancer Immunol Immunother. 2011 May;60(5):671-83. doi: 10.1007/s00262-011-0984-8. Epub 2011 Feb 16.

27.

Evolution of the Ikaros gene family: implications for the origins of adaptive immunity.

John LB, Yoong S, Ward AC.

J Immunol. 2009 Apr 15;182(8):4792-9. doi: 10.4049/jimmunol.0802372.

Supplemental Content

Support Center